Science · 1975 · 127 citations · 11 references
MedicinePharmacologyPharmacotherapyNeuropharmacologyPsychopharmacologySubstance Use DisordersAddictionCannabinoid PharmacologyDetoxification SupportDrugs Of AbuseOpioid AnalgesicsOpioid PharmacologyAbstinence PromotionAbstinence ReinforcementCannabinoid AnalgesicsCannabinoid AntagonistsDetoxificationSubcutaneous Naloxone AdministrationSustained Abstinence
Male rats were implanted subcutaneously with a pellet containg 75 milligrams of morphine base or placebo, and naloxone hydrochloride (4 milligrams per kilogram of body weight) was administered 72 hours later. Treatment with delta-9-tetrahydrocannabinol (2, 5, or 10 milligrams per kilogram) 1 hour before maloxone administration significantly reduced the intensity of abstinence; the two higher doses blocked the appearance of wet shakes and escapes, diarrhea, and increased defecation. delta-9-Tetrahydrocannabinol did not induce abstinence itself, and prior treatment with cannabidiol was ineffective in reducing naloxoneprecipitated abstinence in animals with morphine pellets. These data suggest that delta-9-tetrahydrocannabinol may be of value in facilitating narcotic detoxification.
11
Chemical Basis of Hashish Activity
Raphael Mechoulam, Arnon Shani, H. Edery et al. · Science · 1970 · 330 citations
Behavioral evidence for dopaminergic supersensitivity after chronic haloperidol
Gerald Gianutsos, Richard Drawbaugh, Martin D. Hynes et al. · Life Sciences · 1974 · 195 citations
Medicine, Neuroscience, Pharmacology +15
Studies on Marihuana and Pyrahexyl Compound
Edwin G. Williams, C. K. Himmelsbach, Abraham Wikler et al. · Public Health Reports (1896-1970) · 1946 · 156 citations